Conference abstract · 24 Aug 2015
Conference abstractPublished 8 Aug 2016
Integration of genomics with metabolomics and epigenomics and its implication in cancer control
National Cancer Institute-National Institutes of Health, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Precision medicine is an emerging science with the potential to improve early cancer diagnosis and enable the development of treatment based on an individualâÂ?Â?s genetic background, family history and other characteristics. Identifying patients who may benefit from personalized and precision therapy depends on identifying accurate assays for the biomarkers that are needed to determine optimal treatment. Compared to the rapid progress in technology development, the progress in treatment timing has been slow. Most clinicians rely on pathology reports that become available in due time, which often is too late to control or treat cancer. Molecular profiling (mostly omics profiling based on genomics, metabolomics, epigenomics, transcriptomics and glycomics data) and molecular classification of cancer can be achieved in real time and may help to identify those cancer-associated biomarkers that are expressed much earlier than pathological symptoms and characteristics appear in histopathological analyses. Once these biomarkers are included in personalized medicine, it will enable treatment to be implemented earlier, which will produce better outcomes. Although the traditional approach to personalized medicine has been âÂ?Â?reactiveâÂ? in the future, it will be âÂ?Â?Proactive.âÂ? These approaches might be useful in controlling cancer which is a priority at the National Cancer Institute (NCI) and the National Institutes of Health (NIH). An update from the Common Fund Metabolomics, Epigenomics Roadmap, Molecular Transducers of Physical Activity and the Cancer Genome Atlas (TCGA) will be presented.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 9 Dec 2015
Cancer control by integrating epigenomics and genomics: Are we ready for the prime time?
Opinion · 27 Nov 2024
Harnessing Tumor Genomics and Epigenomics to Personalize Cancer Therapy
Conference abstract · 2018
Network integration of epigenomic data: Leveraging the concept of master regulators in ER negative breast cancer
Commentary · 29 Feb 2024
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic vs. Genomic Biomarkers in Cancer Care
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Mukesh Verma”

